GLP-1 Medications for Weight Loss: How They Work

Have you ever wondered why your body seems to fight back every time you try to lose weight? You eat less, exercise more, and see results for a few weeks. Then the hunger returns stronger than before, and the weight creeps back. It is not a failure of willpower. It is your biology doing exactly what it was designed to do: protect your energy reserves.

So how do GLP-1 medications work to change this? They target the root of the problem -- the hormonal signals that drive hunger, slow your metabolism, and push your body to regain lost weight. Rather than asking you to white-knuckle through another calorie deficit, these medications work with your body's own systems to reduce appetite, slow digestion, and improve metabolic function. In the landmark STEP 1 clinical trial, patients on semaglutide lost an average of 14.9% of their body weight over 68 weeks -- roughly six times more than those on placebo.

In this article, we break down the science behind GLP-1 medications in plain language. You will learn what happens in your brain and gut when you take them, how the major medications (Ozempic, Wegovy, Rybelsus, Mounjaro) compare, what to expect when starting treatment, and what this means for patients in Singapore.

What is GLP-1 and why does it matter for weight loss?

GLP-1 stands for glucagon-like peptide-1. It is a hormone your body produces naturally, mainly in the gut, every time you eat. When food enters your digestive system, specialised cells in your intestines release GLP-1 into your bloodstream, where it does three important things.

First, it signals your pancreas to release insulin, which helps move sugar from your blood into your cells for energy. Second, it tells your brain -- specifically the hypothalamus, your appetite control centre -- that you have eaten enough and can stop. Third, it slows down how quickly food leaves your stomach, so you feel full for longer after a meal.

The problem is that natural GLP-1 breaks down extremely fast. An enzyme called DPP-4 destroys it within one to two minutes of release. That brief window is enough to help regulate blood sugar after a meal, but it is not long enough to produce significant appetite suppression or weight loss on its own.

This is where GLP-1 receptor agonists come in. They are engineered versions of the natural hormone, modified to resist breakdown by DPP-4. Instead of lasting two minutes, injectable semaglutide (the active ingredient in Ozempic and Wegovy) has a half-life of about one week. That means a single weekly injection provides continuous appetite suppression, 24 hours a day, for seven days.

How GLP-1 medications work in your brain

The most powerful effect of GLP-1 medications happens in your brain. Understanding this mechanism explains why patients often describe the experience as "the food noise finally going quiet."

Appetite centres in the hypothalamus

Your hypothalamus contains two opposing sets of neurons that regulate hunger. The first set -- NPY/AgRP neurons -- drives hunger. When these fire, you feel the urge to eat. The second set -- POMC/CART neurons -- promotes satiety. When these activate, you feel full and lose interest in food.

In many people who struggle with weight, the hunger neurons are overactive. You feel hungry even when your body has plenty of stored energy. GLP-1 medications shift this balance by suppressing NPY/AgRP (hunger) neurons and activating POMC/CART (satiety) neurons. The result is a genuine reduction in appetite -- not the kind of forced restraint that comes from counting calories, but a natural quieting of hunger signals.

The brainstem connection

GLP-1 receptors also exist in the nucleus of the solitary tract (NTS) in your brainstem, which receives signals directly from your gut via the vagus nerve. When GLP-1 medications activate these receptors, your brain gets a sustained "fullness" message -- even between meals. This is why patients on GLP-1 medications often report eating smaller portions without consciously trying, and forgetting about food between meals.

Reducing food noise and cravings

Beyond pure hunger suppression, GLP-1 medications appear to affect the brain's reward pathways. Emerging research suggests they dampen the dopamine response to highly palatable foods -- the crisps, cakes, and sugary drinks that normally trigger cravings. This is what patients mean when they talk about food noise disappearing. The constant mental chatter about what to eat next, the pull towards the office snack drawer at 3pm, the urge to finish everything on the plate -- these signals become quieter.

For women dealing with hormonal fluctuations from PCOS, perimenopause, or thyroid conditions, this effect can be particularly meaningful. Hormonal shifts often amplify hunger signals, making weight loss feel impossible despite genuine effort. GLP-1 medications help level the playing field by working at the same biological level as these hormonal disruptions. If hormonal weight challenges resonate with you, our guide on PCOS weight loss options covers this in detail.

How GLP-1 medications affect your digestive system

While the brain effects drive appetite suppression, GLP-1 medications also produce significant changes in your digestive system that support weight loss.

Delayed gastric emptying

GLP-1 medications slow the rate at which food moves from your stomach into your small intestine. This is called delayed gastric emptying. When food stays in your stomach longer, you feel physically full for an extended period after eating. You are less likely to snack between meals, and you naturally eat smaller portions at your next meal.

This mechanism also helps with blood sugar control. By slowing digestion, GLP-1 medications prevent the sharp glucose spikes that typically follow carbohydrate-heavy meals. For Singaporeans navigating a food culture built around rice, noodles, and hawker fare, this steadier glucose response can reduce the energy crashes and subsequent cravings that often follow meals.

Improved insulin response

GLP-1 medications enhance glucose-dependent insulin secretion -- meaning they help your pancreas release insulin more effectively, but only when blood sugar is actually elevated. This is an important safety feature: unlike older diabetes medications, GLP-1 receptor agonists carry a low risk of hypoglycaemia (dangerously low blood sugar) when used for weight management.

They also suppress glucagon, a hormone that raises blood sugar by telling the liver to release stored glucose. By reducing unnecessary glucagon release, GLP-1 medications help keep blood sugar stable throughout the day.

Metabolic benefits beyond weight loss

GLP-1 medications do more than suppress appetite and slow digestion. Clinical trials have documented a range of metabolic improvements that go beyond the number on the scale.

Cardiovascular protection stands out as one of the most significant findings. The SELECT trial demonstrated that semaglutide reduced major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) by 20% in adults with obesity and established cardiovascular disease, even in those without diabetes. The LEADER trial showed that liraglutide 1.8 mg (the diabetes dose, not the weight loss dose of 3.0 mg) reduced major cardiovascular events by 13% (hazard ratio 0.87) in patients with type 2 diabetes over 3.8 years.

On the lipid front, these medications improve cholesterol and triglyceride levels. In the SURMOUNT-1 trial, tirzepatide 15 mg reduced triglycerides by 20-25% compared to placebo, alongside reductions in systolic blood pressure of approximately 6-8 mmHg.

GLP-1 medications also reduce chronic low-grade inflammation, a hallmark of obesity that contributes to insulin resistance and cardiovascular risk. And they preferentially reduce visceral fat -- the metabolically dangerous fat stored around organs -- rather than just the subcutaneous fat beneath your skin. Visceral fat is strongly linked to type 2 diabetes, cardiovascular disease, and metabolic syndrome, so reducing it has health benefits that extend well beyond what the scale shows.

These metabolic improvements are why your doctor may recommend GLP-1 treatment even if your primary goal is health improvement rather than a specific weight target. For more on the long-term metabolic impact, read our article on GLP-1 for long-term weight loss.

Comparing GLP-1 medications available in Singapore

Several GLP-1 medications are available in Singapore, each with distinct characteristics. Understanding the differences can help you have a more informed conversation with your doctor.

Semaglutide: Ozempic, Wegovy, and Rybelsus

Semaglutide is the most widely studied GLP-1 medication for weight loss. It is available in three branded forms, each serving different clinical purposes.

Wegovy is the injectable form specifically approved for weight management at a maintenance dose of 2.4 mg weekly. In the STEP 1 trial (Wilding et al., NEJM 2021), participants without diabetes lost an average of 14.9% of their body weight over 68 weeks. Among those participants, 86.4% lost more than 5% of their body weight, 69.1% lost more than 10%, and 32% lost more than 20%. The STEP 5 trial (Garvey et al., Nat Med 2022) confirmed these results hold over two years, with participants maintaining 15.2% weight loss at 104 weeks.

Ozempic contains the same active ingredient but at lower doses (up to 2 mg per week). It is primarily approved for type 2 diabetes management and is sometimes prescribed off-label for weight loss.

Rybelsus is the oral tablet form of semaglutide, taken daily. At the currently approved 14 mg dose, it produces more modest weight loss of approximately 3-5% in clinical trials (PIONEER programme, primarily in patients with type 2 diabetes). Newer high-dose oral formulations are in development. The OASIS 1 trial demonstrated 15.1% weight loss at 68 weeks with a 50 mg daily dose, approaching injectable-level results.

Want to compare the oral and injectable options? Read our detailed breakdown of oral vs injectable GLP-1 formats.

Tirzepatide: Mounjaro

Tirzepatide (branded as Mounjaro) works differently from pure GLP-1 medications. It is a dual agonist, activating both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors -- a "twincretin" that targets two hormonal pathways at once.

The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) produced the largest weight reductions seen in any GLP-1 class trial. At the 15 mg dose, participants achieved 20.9% weight loss using the intention-to-treat estimate (22.5% in the efficacy estimand for those who stayed on treatment) over 72 weeks. Even the lowest 5 mg dose produced 15.0% weight loss. At the highest dose, 39.7% of participants in the efficacy analysis lost 25% or more of their body weight.

Liraglutide: Saxenda

Liraglutide (branded as Saxenda for weight management) was one of the first GLP-1 medications approved for obesity. It requires daily injections and produces approximately 8.0% weight loss in non-diabetic patients over 56 weeks (SCALE Obesity trial, Pi-Sunyer et al., NEJM 2015). While effective, it has been largely overtaken by semaglutide and tirzepatide, which produce greater weight loss with less frequent dosing.

What to expect when starting GLP-1 treatment

Starting GLP-1 medication involves a gradual dose escalation designed to minimise side effects and give your body time to adjust. Here is what the process looks like in practice.

How dose escalation works

All GLP-1 medications start at a low dose, which is increased over several weeks or months to reach the full therapeutic level.

For injectable semaglutide (Wegovy), the schedule follows five steps: 0.25 mg weekly for the first four weeks, then 0.5 mg for weeks five through eight, 1.0 mg for weeks nine through twelve, 1.7 mg for weeks thirteen through sixteen, and finally the maintenance dose of 2.4 mg weekly from week seventeen onwards.

For oral semaglutide (Rybelsus), dosing begins at 3 mg daily for the first month (a tolerability dose, not yet therapeutic), increases to 7 mg daily in month two, and reaches 14 mg daily from month three onwards. The tablet must be taken on an empty stomach with no more than 120 ml of water, at least 30 minutes before your first food or drink of the day.

For tirzepatide (Mounjaro), dosing starts at 2.5 mg weekly and increases by 2.5 mg every four weeks. Available doses range from 2.5 mg to 15 mg, and your doctor will determine the right maintenance dose based on your response and tolerability.

This gradual approach is deliberate. Jumping to the full dose immediately would produce more intense nausea and gastrointestinal side effects. Starting low and escalating slowly gives your digestive system time to adapt at each level.

Managing common side effects

The most frequently reported side effects are gastrointestinal: nausea, occasional vomiting, diarrhoea, or constipation. These are usually mild to moderate in severity and tend to improve within the first two to four weeks at each dose level as your body adjusts.

Practical strategies that help during the adjustment period include eating smaller, more frequent meals, choosing blander foods when nausea is present, staying well hydrated throughout the day, avoiding very rich, greasy, or spicy dishes, and eating slowly until you feel comfortably satisfied rather than stuffed.

For a full guide on what to watch for and how to manage it, see our article on common GLP-1 side effects.

Serious side effects are rare but important to know about. Contact your doctor immediately if you experience severe abdominal pain (which could indicate pancreatitis), persistent vomiting, or signs of an allergic reaction. GLP-1 medications are contraindicated for people with a personal or family history of medullary thyroid carcinoma (a rare type that accounts for only 3-4% of all thyroid cancers) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). They should also be discontinued at least two months before a planned pregnancy.

When you can expect to see results

Most patients notice reduced appetite within the first one to two weeks, even at the lowest starting dose. Meaningful weight loss typically becomes visible between weeks four and eight. By the time you reach the maintenance dose (around week 16-20 for semaglutide), the full effects on appetite suppression and metabolism are established.

The weight loss trajectory is not a straight line. Some weeks you will lose more, others less, and occasional plateaus are completely normal. What matters is the overall downward trend. In the STEP 1 trial, participants continued losing weight throughout the full 68-week study, and the STEP 5 trial showed sustained results at 104 weeks -- suggesting that patience and consistency pay off.

GLP-1 treatment in Singapore: cost, eligibility, and access

Who qualifies for GLP-1 medication?

GLP-1 medications are prescription-only in Singapore. According to MOH Clinical Practice Guidelines, pharmacotherapy for obesity is recommended for patients with a BMI of 30 or above without comorbidities, or BMI 27.5 or above with weight-related conditions such as type 2 diabetes, hypertension, or dyslipidaemia.

Trimly's eligibility criteria are slightly broader: BMI 27.5 or above without conditions, or BMI 24 or above with weight-related conditions including PCOS, hypertension, or type 2 diabetes. To put those numbers in context, for a woman who is 160 cm tall, a BMI of 24 corresponds to about 61 kg, and a BMI of 27.5 corresponds to about 70 kg.

A licensed doctor assesses your medical history, current medications, and health goals during a video consultation to determine whether GLP-1 treatment is appropriate. To learn more about what doctors evaluate, read about the factors doctors check before prescribing GLP-1.

What does GLP-1 treatment cost in Singapore?

GLP-1 medications are a meaningful financial commitment. Trimly offers all-inclusive plans starting from $350 per month, which covers the video consultation, medication, home delivery, and unlimited follow-up appointments. There are no separate consultation fees or hidden charges.

These medications are generally not covered by Medisave or standard health insurance when prescribed for weight loss. If prescribed for type 2 diabetes, some integrated shield plans may offer partial coverage, but pre-approval is typically required. Coverage policies are evolving, so it is worth checking with your insurer for the most current details.

How telehealth makes treatment more accessible

Traditional weight loss clinics require in-person visits for every consultation, follow-up, and prescription renewal. For busy professionals and parents in Singapore, taking time off work or arranging childcare can be a real barrier to starting -- or continuing -- treatment.

Trimly's MOH-licensed telehealth model removes this friction. The entire process happens online: you complete a health questionnaire, have a video consultation with a licensed doctor, receive a personalised treatment plan, and get your medication delivered to your doorstep. Follow-up consultations for dose adjustments and progress monitoring are unlimited and included in your plan. You also have access to responsive doctor support via WhatsApp between scheduled appointments.

This model is well-suited to GLP-1 treatment specifically, which requires ongoing medical supervision and periodic dose adjustments over several months. With telehealth, your doctor can monitor your progress and make changes without requiring you to rearrange your day.

Frequently asked questions about how GLP-1 medications work

How quickly do GLP-1 medications start working?

Most patients notice a reduction in appetite within the first one to two weeks, even at the lowest starting dose. Clinically meaningful weight loss -- typically 5% or more of body weight -- usually occurs within the first two to three months. Full effects develop as the dose is gradually increased to the maintenance level over 16 to 20 weeks.

Do GLP-1 medications work without diet and exercise?

GLP-1 medications do produce weight loss on their own, but results are significantly better when combined with a balanced diet and regular physical activity. In the STEP 3 trial, semaglutide combined with intensive behavioural therapy produced 16.0% weight loss over 68 weeks, compared to 14.9% in STEP 1 with standard lifestyle counselling. The medication handles the biological side -- reducing hunger and cravings -- while lifestyle changes help build habits that sustain results over the long term.

Are the weight loss results permanent?

Weight loss is maintained as long as treatment continues. The STEP 5 trial showed sustained weight loss of 15.2% at 104 weeks (two years) with continued semaglutide use. However, the STEP 4 trial demonstrated that patients who discontinued treatment after 20 weeks regained roughly two-thirds of their lost weight within the following year. This is why your doctor will discuss a long-term plan and help you build sustainable habits during treatment to support lasting results.

What is the difference between GLP-1 medications and traditional diet pills?

Traditional appetite suppressants like phentermine (Duromine) work by stimulating your central nervous system -- raising norepinephrine levels to suppress appetite. They are approved for short-term use only (up to 12 weeks) and can raise heart rate and blood pressure. GLP-1 medications work through an entirely different mechanism: they mimic a natural gut hormone. They are designed for long-term use and have demonstrated cardiovascular benefits rather than cardiovascular risks.

Can I take GLP-1 medication if I have PCOS?

Yes. GLP-1 medications may be particularly beneficial for women with PCOS, where insulin resistance and hormonal imbalances make weight loss exceptionally difficult. By improving insulin sensitivity and reducing appetite, GLP-1 medications address two of the core metabolic challenges PCOS creates. Your doctor will assess your full medical history to determine the best approach.

Key takeaways on how GLP-1 medications work

GLP-1 medications work by mimicking a hormone your body already produces, extending its effects from minutes to days. They reduce appetite through direct action on brain hunger centres, slow digestion so you feel full longer, and improve metabolic markers including blood sugar, cholesterol, and cardiovascular risk.

The clinical evidence is strong:

• Semaglutide (Wegovy): 14.9% average weight loss over 68 weeks in STEP 1, sustained at 15.2% over two years in STEP 5
• Tirzepatide (Mounjaro): up to 20.9% weight loss over 72 weeks in SURMOUNT-1
• Liraglutide (Saxenda): 8.0% weight loss over 56 weeks in SCALE Obesity

These are not marginal improvements. They represent a genuine shift in what is medically achievable for weight management.

But medications alone are one part of the picture. The best outcomes come from combining GLP-1 treatment with ongoing medical supervision, thoughtful dietary adjustments, and regular physical activity. That is exactly what a structured, doctor-led programme provides.

If you have been struggling with weight despite genuine effort -- if you have done the diets, pushed through the plateaus, and still felt like your body was working against you -- the problem may not be what you are doing. It may be the biology driving your hunger. GLP-1 medications address that biology directly, and a doctor can help you figure out whether they are the right option for you.

GLP-1 medications are prescription-only and require medical assessment. Individual results vary. Always consult a qualified doctor before starting any weight loss treatment.